Cardiac Resynchronization Therapy News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Press Release: Medtronic receives FDA approval for attain Performa Quadripolar lead and Viva Quad CRT-Ds in United States
New system helps physicians deliver cardiac resynchronization therapy optimally and efficiently to heart failure patients.
MedtronicPress Release, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more (Source: Mass Device)
Source: Mass Device - August 8, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news
QRS-Based CRT Advantage for Women in Mild HF: Meta-AnalysisQRS-Based CRT Advantage for Women in Mild HF: Meta-Analysis
Survival went up significantly from cardiac resynchronization therapy across a wider range of QRS durations in women compared with men, with implications for gender-based guidelines. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
Women Helped by CRT More Than Men
(MedPage Today) -- Among patients with left bundle branch block (LBBB) and mild heart failure, women derive a benefit from cardiac resynchronization therapy (CRT) at shorter QRS durations compared with men, an FDA analysis showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 23, 2014 Category: Consumer Health News Source Type: news
EHRA White Book 2014 highlights growing use of complex therapies for heart rhythm abnormalities
(European Society of Cardiology) The White Book contains data on the use of cardiovascular implantable electronic devices including pacemakers, implantable cardiac defibrillators, cardiac resynchronization therapy devices, and lead extractions procedures in Europe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2014 Category: Global & Universal Source Type: news
Consumer Information on: Medtronic CRT-P Devices - P010015S205
A Cardiac Resynchronization Therapy (CRT) device is a special pacemaker designed to treat symptoms of heart failure by sending specially timed electrical impulses to improve the timing, or resynchronize pumping action of the heart's lower chambers (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 9, 2014 Category: Medical Equipment Source Type: news
Consumer Information on: Medtronic CRT-D Devices - P010031S381
A Cardiac Resynchronization Therapy (CRT) device is a special pacemaker designed to treat symptoms of heart failure by sending specially timed electrical impulses to improve the timing, or resynchronize pumping action of the heart's lower chambers (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 9, 2014 Category: Medical Equipment Source Type: news
Medtronic Viva Cardiac Resynchronization Therapy-Pacemaker Now Available In Europe
Medtronic, Inc. recently announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P. The Viva CRT-P is not approved for sale in the United States. (Source: Medical Design Online News)
Source: Medical Design Online News - May 2, 2014 Category: Medical Equipment Source Type: news
Medtronic wins E.U. approval for adaptive, diagnostic Viva pacemaker
Medtronic launches European sales of its Viva CRT-P, which self-adjusts to adapt to patients' heart rhythms and provides diagnostic insight into a patient's physiology.
Minnesota medtech titan Medtronic (NYSE:MDT) launched European sales of its Viva cardiac resynchronization therapy-pacemaker after landing a win from overseas regulators.
MedtronicNews Well, Regulatory/Clearance, Cardiac Rhythm Management, CE Mark, Minnesotaread more (Source: Mass Device)
Source: Mass Device - May 1, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news
IN-TIME analysis reveals equal telemonitoring benefits for ICD and CRT-D devices
Heart failure patients receive similar benefits from implantable devices fitted with telemonitoring technology alerting medical experts to problems regardless of whether they are fitted with cardioverter defibrillators (ICD) or cardiac resynchronization therapy defibrillators (CRT-D), reported the latest analysis of the IN-TIME trial in yesterday’s Late Breaking Trial session.
Topics:
Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - April 23, 2014 Category: Cardiology Source Type: news
Medtronic CRT Devices Now Approved To Treat Patients With AV Block And Reduced Heart Function
Medtronic, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators (CRT-P and CRT-D). (Source: Medical Design Online News)
Source: Medical Design Online News - April 17, 2014 Category: Medical Equipment Source Type: news
FDA Clears CRT Devices for More HF Patients
(MedPage Today) -- The FDA has expanded the indication for several cardiac resynchronization therapy devices made by Medtronic to include patients with atrioventricular block and milder heart failure. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 11, 2014 Category: Cardiology Source Type: news
ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients
Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure.
Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend.
American College of Cardiology, Boston Scientific, Abbott LaboratoriesNews Well, Clinical Trials, ACC 2014, Bariatrics, Diabetes, Replacement Heart Valves, Stent Warsread more (Source: Mass Device)
Source: Mass Device - March 31, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news
Cardiac resynchronization improves survival in heart failure patients
Patients in mild heart failure who receive a specialized pacemaker known as cardiac resynchronization therapy with a defibrillator may live longer than those implanted with a traditional implantable cardioverter defibrillator, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 31, 2014 Category: Science Source Type: news
Survival Benefit Found After Long-Term Resynchronization Therapy
MADIT-CRT was an influential trial that showed a reduction in heart failure complications — but not mortality — when cardiac resynchronization therapy (CRT) was added to an implantable defibrillator in patients with mild heart failure who also had left bundle-branch block (LBBB). Patients in the trial were followed for 2.4 years, raising questions about the long-term effects of CRT. Now, a second look at 854 patients who participated in a follow-up study, presented at the American College of Cardiology and published in the New England Journal of Medicine, suggests that over the long ter...
Source: Forbes.com Healthcare News - March 30, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Three New St. Jude Pacemakers Cleared For U.S. Market
St. Jude Medical announced earlier this week that the FDA has granted approval for the Allure Quadra Cardiac Resynchronization Therapy Pacemaker (CRT-P), along with the Assurity and Endurity families of pacemakers. (Source: Medical Design Online News)
Source: Medical Design Online News - March 26, 2014 Category: Medical Equipment Source Type: news
